Pannexins in Acute Kidney Injury.

Nephron

Division of Nephrology and Center for Immunity, Inflammation, and Regenerative Medicine, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA,

Published: July 2020

Acute kidney injury (AKI) is highly prevalent among hospitalized patients and is associated with serious consequences with limited pharmacological treatment options. Pannexin 1 (Panx1) channel is a ubiquitously expressed nonselective membrane transport channel that efficiently effluxes ATP and plays a central role in the progression of inflammatory diseases. Animal models that target Panx1 through pharmacological inhibition or genetic deficiency have better outcomes in minimizing inflammation and associated pathology. Given the involvement of Panx1 at multiple steps of -inflammatory pathology, Panx1 could be a potential therapeutic target in the treatment of AKI. Further research is needed in elaborating the mechanisms and identifying Panx1-specific inhibitor molecules to better understand the role of Panx1 in AKI pathology arising due to diverse insults.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821569PMC
http://dx.doi.org/10.1159/000501278DOI Listing

Publication Analysis

Top Keywords

acute kidney
8
kidney injury
8
panx1
5
pannexins acute
4
injury acute
4
injury aki
4
aki highly
4
highly prevalent
4
prevalent hospitalized
4
hospitalized patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!